Cargando…
Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
Atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) is thought to preclude shunt closure. However, there are several reports that vasodilator treatment is associated with good clinical outcome in these patients, recently. We report a case of good clinical outcome in a patien...
Autores principales: | Park, Yong Kyu, Park, Jae-Hyeong, Yu, Jae Hyeon, Kim, Jun Hyung, Lee, Jae-Hwan, Choi, Si Wan, Jeong, Jin-Ok, Seong, In-Whan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Echocardiography
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209598/ https://www.ncbi.nlm.nih.gov/pubmed/22073329 http://dx.doi.org/10.4250/jcu.2011.19.3.159 |
Ejemplares similares
-
Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007) -
Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009) -
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009) -
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009) -
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)